Omega Therapeutics, Inc. (OMGAQ)

Market Cap	1.77M
Revenue (ttm)	8.10M
Net Income (ttm)	-73.09M
Shares Out	55.37M
EPS (ttm)	-1.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,104
Average Volume	151,142
Open	0.0310
Previous Close	0.0320
Day's Range	0.0296 - 0.0330
52-Week Range	0.0100 - 0.1900
Beta	0.64
RSI	43.33
Earnings Date	Aug 1, 2025

About Omega Therapeutics

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company’s OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 94
• Stock Exchange: OTCMKTS
• Ticker Symbol: OMGAQ

Financial Performance

In 2023, Omega Therapeutics's revenue was $3.09 million, an increase of 49.25% compared to the previous year's $2.07 million. Losses were -$97.43 million, -5.13% less than in 2022.